A statin result that looks smaller than expected

A follow-up lipid panel comes back six weeks after a patient started high-intensity statin therapy for established atherosclerotic cardiovascular disease. Baseline LDL-C, calculated by the Friedewald equation, was 165 mg/dL. The week-6 result on the same analyzer, same reagent lot, and confirmed fasting collection is 93 mg/dL. That is a 44 percent reduction. High-intensity statin therapy is expected to produce roughly 50 percent or more reduction from an untreated baseline. The number moved in the right direction, and it is still below what the dose class predicts.

The medication history confirms daily use with no missed doses reported. The specimen is non-hemolyzed, non-lipemic, and fasting was confirmed at both draws. Non-HDL-C moved from 195 to 119 mg/dL, tracking LDL-C, so the panel is internally consistent. Nothing here points to a compromised specimen or a calculation error. The bench question is whether the two results are analytically comparable before calculating and describing this case-specific percentage change.

The drug classes in current use, the case-specific timing, and the checks a laboratory runs on specimen integrity, method continuity, and internal consistency all matter before treating a lipid trend as a true biological or treatment-related change. The laboratory does not decide whether the statin is working. The laboratory decides whether the two numbers being compared are actually comparable.

Calculate the case-specific percentage only after confirming the two results are comparable; the percentage itself does not direct a laboratory note, comment, hold, or release action.